Morica Hutchison, Beth S. Russell, Abigail Leander, Nathaniel Rickles, Derek Aguiar, Xiaomei S. Cong, Ofer Harel, Adrian V. Hernandez
{"title":"Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis","authors":"Morica Hutchison, Beth S. Russell, Abigail Leander, Nathaniel Rickles, Derek Aguiar, Xiaomei S. Cong, Ofer Harel, Adrian V. Hernandez","doi":"10.1177/00220426231204841","DOIUrl":null,"url":null,"abstract":"Adherence to and retention in Medication Treatment for Opioid Use Disorders (MOUD) persist. We systematically reviewed trends of USA MOUD adherence, retention, and barriers from 2011–2021. Primary outcomes were adherence to and retention in MOUD, abstinence, adverse events, and treatment barriers. Effects of inverse variance random meta-analyses were examined using proportions and 95% CIs. 28 studies (102,318 patients), 78.1% male. Adherence was 56% across all studies, highest for methadone (73%). Retention by study design was heterogeneous: case series (57%), cohorts (47%), and RCTs (70%). The most common barriers were younger age, comorbid diagnoses, daily attendance, no insurance, and transportation. Abstinence was 72%, and adverse events was 5%. There was high heterogeneity in MOUD across drug types and study designs. Our findings extend the knowledge base of MOUD treatment to describe barriers that underpin the focus on retention in care above adherence given its focus to harm reduction principles.","PeriodicalId":15626,"journal":{"name":"Journal of Drug Issues","volume":"83 1","pages":"0"},"PeriodicalIF":1.2000,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Issues","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00220426231204841","RegionNum":4,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 1
Abstract
Adherence to and retention in Medication Treatment for Opioid Use Disorders (MOUD) persist. We systematically reviewed trends of USA MOUD adherence, retention, and barriers from 2011–2021. Primary outcomes were adherence to and retention in MOUD, abstinence, adverse events, and treatment barriers. Effects of inverse variance random meta-analyses were examined using proportions and 95% CIs. 28 studies (102,318 patients), 78.1% male. Adherence was 56% across all studies, highest for methadone (73%). Retention by study design was heterogeneous: case series (57%), cohorts (47%), and RCTs (70%). The most common barriers were younger age, comorbid diagnoses, daily attendance, no insurance, and transportation. Abstinence was 72%, and adverse events was 5%. There was high heterogeneity in MOUD across drug types and study designs. Our findings extend the knowledge base of MOUD treatment to describe barriers that underpin the focus on retention in care above adherence given its focus to harm reduction principles.
期刊介绍:
The Journal of Drug Issues (JDI) was incorporated as a nonprofit entity in the State of Florida in 1971. In 1996, JDI was transferred to the Florida State University College of Criminology and Criminal Justice, and the Richard L. Rachin Endowment was established to support its continued publication. Since its inception, JDI has been dedicated to providing a professional and scholarly forum centered on the national and international problems associated with drugs, especially illicit drugs. It is a refereed publication with international contributors and subscribers. As a leader in its field, JDI is an instrument widely used by research scholars, public policy analysts, and those involved in the day-to-day struggle against the problem of drug abuse.